Pursuant to Regulation 30 and 33 of the Listing Regulations, Approved the Audited Standalone and Consolidated Financial Statements for the Fourth quarter and year ended March 31, 2025. In this regard, please find enclosed:Audited Standalone and Consolidated Financial Statements of the Company for the Fourth quarter and year ended March 31, 2025, which had been duly reviewed and recommended by the Audit Committee along with the Auditor s Report with Unmodified opinion thereon
MANORG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Organics has filed its audited Q4 and FY25 results, approved by the board on May 10, 2025. On a standalone basis, revenue from operations rose marginally to Rs. 40,984.75 lakhs (vs Rs. 40,543.35 lakhs in FY24), while total comprehensive income jumped about 86% to Rs. 759.99 lakhs and EPS doubled to Rs. 8.87. On a consolidated basis (including three subsidiaries), revenue grew around 7% to Rs. 53,000.90 lakhs and total comprehensive income nearly tripled to Rs. 1,250.42 lakhs with EPS at Rs. 14.60 (vs Rs. 4.92). Q4 was particularly strong on the consolidated side with revenue up about 42% year-on-year and profit before tax rising to Rs. 659.32 lakhs. The auditor (NGST & Associates) issued an unmodified opinion on both sets of results. Notably, operating cash flow turned sharply negative at Rs. (4,649) lakhs standalone and Rs. (784) lakhs consolidated, while total borrowings climbed to roughly Rs. 25,000–26,000 lakhs, funded mainly through short-term debt.
Profitability has improved sharply with nearly three-fold growth in consolidated earnings and strong Q4 momentum, which is positive for shareholders. However, the swing to negative operating cash flow and a sharp rise in borrowings and finance costs are red flags that investors should watch, as future earnings will depend on managing working capital and debt.